Trials / Recruiting
RecruitingNCT06598306
Subcutaneous Tarlatamab in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-308)
A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-Tumor Activity of Subcutaneous Tarlatamab in Subjects With Extensive Stage Small Cell Lung Cancer (DeLLphi-308)
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 220 (estimated)
- Sponsor
- Amgen · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of this study is to evaluate the safety and tolerability of subcutaneous (SC) tarlatamab.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Tarlatamab | Administered by SC injection. |
Timeline
- Start date
- 2024-10-07
- Primary completion
- 2027-02-01
- Completion
- 2030-03-27
- First posted
- 2024-09-19
- Last updated
- 2025-12-01
Locations
30 sites across 10 countries: United States, Australia, Belgium, China, Germany, Japan, Poland, Spain, Switzerland, Turkey (Türkiye)
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06598306. Inclusion in this directory is not an endorsement.